|
Post by digger on Mar 20, 2018 23:11:26 GMT -5
What I don't see in the slides is anything about insurance. Was anything said about improving coverage? I don't believe mediocre sales reps are part of the problem, and replacing 25 of them doesn't sound like a good solution at this point -- the old saying about changing mules midstream. That may be a good excuse for poor prescription numbers but the fundamental issue far and away is cost and at some point Mike will need to address that.
|
|
|
Post by gamblerjag on Mar 20, 2018 23:18:42 GMT -5
I saw on ST (seems to be deleted now) that Mike said something to the affect that MNKD will not be around in a year or so as we know it. something to that affect.. can't hear him say that on the video.. anyone know where he said that?
|
|
|
Post by babaoriley on Mar 21, 2018 0:41:58 GMT -5
That was far and away Mike's best presentation on behalf of MannKind! Smooth and confident, all the way through! Terrific job, Mike! As to some of his feelings re script counts and how long our money will last before needing to tap markets, well, let's just say I hope that Mike is able to make my pessimism seem short-sighted and unenlightened. Mike, I need to warn you, I've known MannKind far longer than you have.
|
|
|
Post by sportsrancho on Mar 21, 2018 5:01:15 GMT -5
I saw on ST (seems to be deleted now) that Mike said something to the affect that MNKD will not be around in a year or so as we know it. something to that affect.. can't hear him say that on the video.. anyone know where he said that? It is not deleted, and here it is. @kevinmik 3/20/18, 5:38 PM $mnkd Mike made an interesting statement during the calling saying Mannkind & Afrezza is one in the same at least for the next year
|
|
|
Post by goyocafe on Mar 21, 2018 5:28:00 GMT -5
I saw on ST (seems to be deleted now) that Mike said something to the affect that MNKD will not be around in a year or so as we know it. something to that affect.. can't hear him say that on the video.. anyone know where he said that? It is not deleted, and here it is. @kevinmik 3/20/18, 5:38 PM $mnkd Mike made an interesting statement during the calling saying Mannkind & Afrezza is one in the same at least for the next year I interpreted that to mean they have no other products yet, and he is eyeing utilizing their new sales infrastructure to advance other products at some point. Until then, Afrezza and Mannkind are one in the same.
|
|
|
Post by boca1girl on Mar 21, 2018 6:16:53 GMT -5
What I don't see in the slides is anything about insurance. Was anything said about improving coverage? I don't believe mediocre sales reps are part of the problem, and replacing 25 of them doesn't sound like a good solution at this point -- the old saying about changing mules midstream. That may be a good excuse for poor prescription numbers but the fundamental issue far and away is cost and at some point Mike will need to address that. All I heard him mention was CVS, which he already mentioned on the year end earnings call. Nothing new that I heard in this presentation.
|
|
|
Post by sportsrancho on Mar 21, 2018 7:29:39 GMT -5
@gator123 3/21/18, 5:26 AM @rooksleanne living in Fl , everyone i talked to from diabetic to dr and pharmacists never heard of Afrezza or just a few barely.
|
|
|
Post by sportsrancho on Mar 21, 2018 8:12:24 GMT -5
@dgreen908 3/21/18, 6:04 AM @gator123 @rooksleanne I live in NJ same here...I have asked the CVS Pharmacist in multiple locations and they have never heard of it
|
|
|
Post by dreamboatcruise on Mar 21, 2018 11:18:03 GMT -5
That was far and away Mike's best presentation on behalf of MannKind! Smooth and confident, all the way through! Terrific job, Mike! As to some of his feelings re script counts and how long our money will last before needing to tap markets, well, let's just say I hope that Mike is able to make my pessimism seem short-sighted and unenlightened. Mike, I need to warn you, I've known MannKind far longer than you have. What did Mike say about when they'd next need to raise capital? I don't remember anything concrete other than the implication that we'll barely skate by the end of this quarter with the necessary $25M in cash, but would burn through that in Q2 and need to replenish from somewhere, likely meaning dilution in Q2.
|
|
|
Post by goyocafe on Mar 21, 2018 11:20:24 GMT -5
That was far and away Mike's best presentation on behalf of MannKind! Smooth and confident, all the way through! Terrific job, Mike! As to some of his feelings re script counts and how long our money will last before needing to tap markets, well, let's just say I hope that Mike is able to make my pessimism seem short-sighted and unenlightened. Mike, I need to warn you, I've known MannKind far longer than you have. What did Mike say about when they'd next need to raise capital? I don't remember anything concrete other than the implication that we'll barely skate by the end of this quarter with the necessary $25M in cash, but would burn through that in Q2 and need to replenish from somewhere, likely meaning dilution in Q2. I must have mis-heard him. I thought he indicated that organic growth and (other events, my interpretation) would take us through the end of 2018 and that further dilution was not on the table for the balance of 2018. I'm going to listen again. I've been in the MNKD desert too long, I'm seeing and hearing things. Update: Time: 24:52 of presentation. Nothing expected to be needed to meet Deerfield threshold in the near term, but it sounds like the door is still open for something (dilution) to happen this year.
|
|
|
Post by dreamboatcruise on Mar 21, 2018 11:42:41 GMT -5
What did Mike say about when they'd next need to raise capital? I don't remember anything concrete other than the implication that we'll barely skate by the end of this quarter with the necessary $25M in cash, but would burn through that in Q2 and need to replenish from somewhere, likely meaning dilution in Q2. I must have mis-heard him. I thought he indicated that organic growth and (other events, my interpretation) would take us through the end of 2018 and that further dilution was not on the table for the balance of 2018. I'm going to listen again. I've been in the MNKD desert too long, I'm seeing and hearing things. Update: Time: 24:52 of presentation. Nothing expected to be needed to meet Deerfield threshold in the near term, but it sounds like the door is still open for something (dilution) to happen this year. Near term as in getting us through Q1. It is interesting how easy it is to hear things that we wish to hear when it's really not there.
|
|
|
Post by mytakeonit on Mar 21, 2018 13:09:14 GMT -5
Yeah, it's like not having a nose to smell ... and end up eating a bug.
|
|
|
Post by buyitonsale on Mar 21, 2018 13:36:31 GMT -5
in Q2 they should have at least 2 announcements (One Drop collaboration and International agreement).
|
|
|
Post by mannmade on Mar 21, 2018 13:56:13 GMT -5
in Q2 they should have at least 2 announcements (One Drop collaboration and International agreement). And don’t forget reveal of STAT study in June at ADA...
|
|
|
Post by dreamboatcruise on Mar 21, 2018 15:50:37 GMT -5
in Q2 they should have at least 2 announcements (One Drop collaboration and International agreement). I bet they'll have even more than 2 announcements. What they'll be is always hard to predict, but historically speaking we usually get more than 2 in a quarter... deals, new employees, debt restructurings, selling shares, etc. I think another private placement is highly likely in Q2.
|
|